Exportin 1 Pipeline Review, H1

1
Exportin 1 Pipeline Review, H1
www.bharatbook.com
2
Summary
According to the recently published
report 'Exportin 1 - Pipeline Review, H1 2017'
Exportin 1 (Chromosome Region Maintenance 1
Protein Homolog or XPO1) pipeline Target
constitutes close to 7 molecules. Out of which
approximately 7 molecules are developed by
Companies.
www.bharatbook.com
3
(No Transcript)
4
Exportin 1 (Chromosome Region Maintenance 1
Protein Homolog or XPO1) - Exportin 1 (XPO1) or
chromosomal maintenance 1 (CRM1) is a eukaryotic
protein. It mediates the nuclear export of
cellular proteins bearing a leucine-rich nuclear
export signal (NES) and of RNAs. In association
with RANBP3, it binds cooperatively to the NES on
its target protein and to the GTPase RAN in its
active Ran-GTP. Docking of this complex to the
nuclear pore complex (NPC) is mediated through
binding to nucleoporins. It is involved in U3
snoRNA transport from Cajal bodies to nucleoli.
www.bharatbook.com
5
The report 'Exportin 1 - Pipeline Review, H1
2017' outlays comprehensive information on the
Exportin 1 (Chromosome Region Maintenance 1
Protein Homolog or XPO1) targeted therapeutics,
complete with analysis by indications, stage of
development, mechanism of action (MoA), route of
administration (RoA) and molecule type that are
being developed by Companies / Universities.
www.bharatbook.com
6
It also reviews key players involved in Exportin
1 (Chromosome Region Maintenance 1 Protein
Homolog or XPO1) targeted therapeutics
development with respective active and dormant
or discontinued projects. Currently, The
molecules developed by companies in Phase III,
Phase II, Phase I and Preclinical stages are 1,
1, 2 and 3 respectively. Report covers products
from therapy areas Oncology, Central Nervous
System, Genetic Disorders, Immunology and
Infectious Disease which include indications
Acute Lymphocytic Leukemia
www.bharatbook.com
7
(ALL, Acute Lymphoblastic Leukemia), Prostate
Cancer, Acute Myelocytic Leukemia (AML, Acute
Myeloblastic Leukemia), Diffuse Large B-Cell
Lymphoma, Hematological Tumor, Malignant
Mesothelioma, Melanoma, Multiple Myeloma (Kahler
Disease), Myelodysplastic Syndrome, Non-Small
Cell Lung Cancer, Refractory Multiple Myeloma,
Relapsed Multiple Myeloma, Amyotrophic Lateral
Sclerosis, B-Cell Leukemia, Bone Sarcoma, Burkitt
Lymphoma, Cervical Cancer, Chondrosarcoma,
Chronic Myelocytic Leukemia (CML, Chronic Myeloid
Leukemia), Colon Cancer, Colorectal Cancer,
Duchenne Muscular Dystrophy, Endometrial Cancer,
Equine Encephalitis, Fallopian Tube Cancer,
Follicular Lymphoma, Gastrointestinal Tract
Cancer, Hepatitis C, Human Immunodeficiency Virus
(HIV) Infections (AIDS), Human Papillomavirus
(HPV)
www.bharatbook.com
8
Associated Cancer, Influenzavirus A Infections,
Leiomyosarcoma, Leukemias, Liposarcoma,
Lymphoma, Mantle Cell Lymphoma, Metastatic
Breast Cancer, Metastatic Colorectal Cancer,
Multiple Sclerosis, Neuroendocrine Tumors,
Non-Hodgkin Lymphoma, Ovarian Cancer,
Pancreatic Cancer, Rectal Cancer, Recurrent
Glioblastoma Multiforme (GBM), Refractory Acute
Myeloid Leukemia, Refractory Chronic Lymphocytic
Leukemia (CLL), Relapsed Acute Myeloid Leukemia,
Relapsed Chronic Lymphocytic Leukemia (CLL),
Renal Cell Carcinoma, Respiratory Syncytial Virus
(RSV) Infections, Rheumatoid Arthritis,
Small-Cell Lung Cancer, Soft Tissue Sarcoma,
Solid Tumor, Synovial Sarcoma, Systemic Lupus
Erythematosus, T-Cell Lymphomas, Thymoma (Thymic
Epithelial Tumor), Traumatic Brain Injury,
Venezuelan Equine Encephalitis and Waldenstrom
Macroglobulinemia.
www.bharatbook.com
9
Scope

• The report provides a snapshot of the
• global therapeutic landscape for Exportin 1
• (Chromosome Region Maintenance 1 Protein
• Homolog or XPO1)
• The report reviews Exportin 1 (Chromosome
• Region Maintenance 1 Protein Homolog
• or XPO1) targeted therapeutics under
• development by companies and universities/research
  institutes based on information derived from
  company and industry-specific sources
• The report covers pipeline products based on
  various stages of development ranging from
  pre-registration till discovery and undisclosed
  stages
• The report features descriptive drug profiles
  for the pipeline products which includes, product
  description, descriptive MoA, RD brief,
  licensing and collaboration details other
  developmental activities

www.bharatbook.com
10

• The report reviews key players involved in
• Exportin 1 (Chromosome Region Maintenance 1
• Protein Homolog or XPO1) targeted therapeutics
• and enlists all their major and minor projects
• The report assesses Exportin 1 (Chromosome
• Region Maintenance 1 Protein Homolog or XPO1)
  targeted therapeutics based on mechanism of
  action (MoA), route of administration (RoA) and
  molecule type
• The report summarizes all the dormant and
  discontinued pipeline projects
• The report reviews latest news and deals related
  to Exportin 1 (Chromosome Region Maintenance 1
  Protein Homolog or XPO1) targeted therapeutics

www.bharatbook.com
11
Reasons to buy

• Gain strategically significant competitor
• information, analysis, and insights to formulate
• effective RD strategies
• Identify emerging players with potentially
• strong product portfolio and create effective
  counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy
  areas and indications for Exportin 1 (Chromosome
  Region Maintenance 1 Protein Homolog or XPO1)
• Identify the use of drugs for target
  identification and drug repurposing
• Identify potential new clients or partners in
  the target demographic

www.bharatbook.com
12

• Develop strategic initiatives by understanding
• the focus areas of leading companies
• Plan mergers and acquisitions effectively by
• identifying key players and its most promising
• pipeline therapeutics
• Devise corrective measures for pipeline projects
  by understanding Exportin 1(Chromosome Region
  Maintenance 1 Protein Homolog or XPO1)
  development landscape
• Develop and design in-licensing and
  out-licensing strategies by identifying
  prospective partners with the most attractive
  projects to enhance and expand business potential
  and scope

www.bharatbook.com
13
Full Report
Exportin 1 Pipeline Review, H1
Contact us at Bharat Book Bureau Tel 91 22
27810772 / 27810773 Email poonam_at_bharatbook.com W
ebsite www.bharatbook.com Our Blog
https//www.bharatbook.com/blog/Follow us on
Twitter https//twitter.com/researchbook Follow
us on Facebook https//www.facebook.com/BharatBoo
k3B Follow us on Linked In http//www.linkedin.c
om/company/bharat-book-bureau